FDA Issues Warnings on Topamax and Actos
NEW WARNING ON DIABETES DRUG
Actos (pioglitazone) is a drug used to treat patients with diabetes that has now been linked to an increased risk of bladder cancer. This warning was added to the label after being approved by the FDA on August 5th 2012. The new warnings come after interim results from a 10-year study showed patients exposed to the drug for long periods of time may face an increased risk of cancer. In fact, the study, published in the Journal of Diabetes Care, shows patients who used pioglitazone had a 40% greater risk of bladder cancer than those who did not use the drug.
If you or someone you know has used Actos in treatment of their diabetes, and has shown symptoms of, or been diagnosed with, bladder cancer, please contact Attorney Peter J. Flowers at (630) 232-6333 or 630-232-6333 for more information.
BIRTH DEFECTS LINKED TO TOPAMAX
The FDA announced on March 4th 2012 it was changing the classification of Topamax (topiramate), an anti-convulsant medication used to treat patients with epilepsy, other types of seizures, and migraine headaches, to pregnancy category D. Category D drugs are those confirmed as presenting a risk of fetal injury. The FDA made the change because of evidence linking Topamax to cleft palates and cleft lips.
If you or someone you know was taken the drug Topamax and had a child born with a cleft palate or lip, please contact Attorney Peter J. Flowers at (630) 232-6333 or 630-232-6333 for more information.